Related papers: Probabilistic Clustering using Shared Latent Varia…
Background: Dementia, marked by cognitive decline, is a global health challenge. Alzheimer's disease (AD), the leading type, accounts for ~70% of cases. Electroencephalography (EEG) measures show promise in identifying AD risk, but…
We consider high-dimensional regression over subgroups of observations. Our work is motivated by biomedical problems, where disease subtypes, for example, may differ with respect to underlying regression models, but sample sizes at the…
Deep learning, a cutting-edge machine learning approach, outperforms traditional machine learning in identifying intricate structures in complex high-dimensional data, particularly in the domain of healthcare. This study focuses on…
Alzheimer's disease (AD), defined as an abnormal buildup of amyloid plaques and tau tangles in the brain can be diagnosed with high accuracy based on protein biomarkers via PET or CSF analysis. However, due to the invasive nature of…
Alzheimer's disease is a progressive neurodegenerative disorder that remains challenging to predict due to its multifactorial etiology and the complexity of multimodal clinical data. Accurate forecasting of clinically relevant biomarkers,…
Early detection of Alzheimer's Disease (AD) and its prodromal state, Mild Cognitive Impairment (MCI), is crucial for providing suitable treatment and preventing the disease from progressing. It can also aid researchers and clinicians to…
Alzheimer's Disease (AD) and related dementia are a growing global health challenge due to the aging population. In this paper, we present ADMarker, the first end-to-end system that integrates multi-modal sensors and new federated learning…
Alzheimer's disease is a neurodegenerative condition that accelerates cognitive decline relative to normal aging. It is of critical scientific importance to gain a better understanding of early disease mechanisms in the brain to facilitate…
Alzheimer's disease is the most common neurodegenerative disease. The aim of this study is to infer structural changes in brain connectivity resulting from disease progression using cortical thickness measurements from a cohort of…
Alzheimer disease (AD) is a neurodegenerative disease that lacks specific treatment options. Natural drugs have displayed neuroprotective effects; however, their high-throughput discovery is challenging because of the expense of…
The uncertainty of clinical examinations frequently leads to irregular observation intervals in longitudinal imaging data, posing challenges for modeling disease progression.Most existing imaging-based disease prediction models operate in…
Alzheimer's Disease (AD) is a neurodegenerative disease that affects subjects in a broad range of severity and is assessed in clinical trials with multiple cognitive and functional instruments. As clinical trials in AD increasingly focus on…
Alzheimer's disease (AD), as a progressive brain disease, affects cognition, memory, and behavior. Similarly, limbic-predominant age-related TDP-43 encephalopathy (LATE) is a recently defined common neurodegenerative disease that mimics the…
Computer-aided early diagnosis of Alzheimers Disease (AD) and its prodromal form, Mild Cognitive Impairment (MCI), has been the subject of extensive research in recent years. Some recent studies have shown promising results in the AD and…
Automated methods for Alzheimer's disease (AD) classification have the potential for great clinical benefits and may provide insight for combating the disease. Machine learning, and more specifically deep neural networks, have been shown to…
Alzheimer's Disease (AD) is a non-curable progressive neurodegenerative disorder that affects the human brain, leading to a decline in memory, cognitive abilities, and eventually, the ability to carry out daily tasks. Manual diagnosis of…
Volume change measures derived from longitudinal MRI (e.g. hippocampal atrophy) are a well-studied biomarker of disease progression in Alzheimer's Disease (AD) and are used in clinical trials to track the therapeutic efficacy of…
Disease modifying therapies for Alzheimer's disease demand precise timing decisions, yet current predictive models require longitudinal observations and provide no uncertainty quantification, rendering them impractical at the critical first…
Most approaches to machine learning from electronic health data can only predict a single endpoint. Here, we present an alternative that uses unsupervised deep learning to simulate detailed patient trajectories. We use data comprising…
We propose a method to predict the subject-specific longitudinal progression of brain structures extracted from baseline MRI, and evaluate its performance on Alzheimer's disease data. The disease progression is modeled as a trajectory on a…